Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2019) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight

(2019) So-Ryoung Lee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Meta-analysis of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients >75 Years of Age

(2019) Aaqib H. Malik et al.   AMERICAN JOURNAL OF CARDIOLOGY

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation

(2019) Eric D. Peterson et al.   AMERICAN HEART JOURNAL

Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data

(2019) Margarita Kushnir et al.   Lancet Haematology

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight

(2019) Stefan H. Hohnloser et al.   CIRCULATION

Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves

(2019) Aaqib H Malik et al.   HEART

Weight change and the risk of incident atrial fibrillation: a systematic review and meta-analysis

(2019) Nicholas R Jones et al.   HEART

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

(2018) Xiaoyan Li et al.   PLoS One

Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation

(2018) Kazuhiko Kido et al.   ANNALS OF PHARMACOTHERAPY

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

(2018) Giuseppe Boriani et al.   EUROPEAN HEART JOURNAL

Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

(2017) Gregory Y H Lip et al.   EUROPACE

Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants

(2017) Chan Soon Park et al.   HEART RHYTHM

Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?

(2017) Marco Proietti et al.   STROKE

The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method

(2014) Joanna IntHout et al.   BMC Medical Research Methodology

Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation

(2012) Hany S. Abed et al.   HEART RHYTHM

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE